Clinical Trials Register

Trials with a EudraCT protocol (151)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

151 result(s) found for: Skin rash. Displaying page 1 of 8.

EudraCT Number: 2011-000877-29

Sponsor Protocol Number: GEOS-01-2011

Start Date*: 2011-12-02

Sponsor Name:Grupo de Estudos Oncológicos

Full Title: Phase III clinical trial for evaluation of prophylactic treatment with minocycline versus reactive treatment of dermatological toxicity secondary to cetuximab in patients with metastatic colorectal...

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	13.1	10040785 - Skin and subcutaneous tissue disorders	10037844	Rash	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PT (Completed)

Trial results: (No results available)

EudraCT Number: 2006-000390-30	Sponsor Protocol Number: ML20128	Start Date*: 2006-05-18
Sponsor Name:Helsinki University Central Hospital, Skin and Allergy Hospital
Full Title: A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash
Medical condition: The study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effec...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)

EudraCT Number: 2021-002818-13

Sponsor Protocol Number: DEALSZ-2021-001

Start Date*: 2023-05-12

Sponsor Name:Charité-Universitätsmedizin Berlin

Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...

Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10040785 - Skin and subcutaneous tissue disorders	10037083	Prurigo	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2017-000608-13

Sponsor Protocol Number: MK-4117-201

Start Date*: 2017-02-09

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria.

Medical condition: Chronic urticaria (a skin condition caused by an allergy)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.1	10040785 - Skin and subcutaneous tissue disorders	10052568	Urticaria chronic	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: Outside EU/EEA

Trial results: View results

EudraCT Number: 2012-003136-23

Sponsor Protocol Number: CRO1990

Start Date*: 2012-11-27

Sponsor Name:Imperial College London

Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness

Medical condition: Borderline Personality Disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10040785 - Skin and subcutaneous tissue disorders	10042033	Stevens-Johnson syndrome	PT
	14.1	10029205 - Nervous system disorders	10019211	Headache	PT
	15.0	100000004856	10028821	Nausea with vomiting	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10040913	Skin rash	LLT
	14.1	10029205 - Nervous system disorders	10024264	Lethargy	PT
	14.1	10029205 - Nervous system disorders	10013649	Drowsiness	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2012-003567-22

Sponsor Protocol Number: Zincox12

Start Date*: 2012-12-05

Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA

Full Title: Efficacy of topical application of zinc oxide ointment compared with zinc oxide paste and tocoferol, for treating diaper dermatitis in infant: a randomized, controlled, triple blind study

Medical condition: Diaper dermatitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10040785 - Skin and subcutaneous tissue disorders	10012444	Dermatitis diaper	PT

Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2020-000169-17

Sponsor Protocol Number: D3259C00001

Start Date*: 2020-12-01

Sponsor Name:AstraZeneca AB

Full Title: A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneo...

Medical condition: chronic spontaneous urticaria

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10040785 - Skin and subcutaneous tissue disorders	10046735	Urticaria	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2020-003494-22

Sponsor Protocol Number: ANB019-207

Start Date*: 2021-02-24

Sponsor Name:AnaptysBio Inc.

Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy

Medical condition: Acneiform Rash

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004858	10037847	Rash acneiform	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) BG (Prematurely Ended) HU (Completed)

Trial results: View results

EudraCT Number: 2019-004739-22

Sponsor Protocol Number: DER-201805

Start Date*: 2021-03-16

Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn

Full Title: Efficacy of ruxolitinib cream in Prurigo nodularis patients: A randomized, placebo-controlled pilot study (PRUX)

Medical condition: Patients with symptomatic Prurigo nodularis with active skin manifestations

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10040785 - Skin and subcutaneous tissue disorders	10037084	Prurigo nodularis	LLT
	20.0	10040785 - Skin and subcutaneous tissue disorders	10037083	Prurigo	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2021-003011-26

Sponsor Protocol Number: BILA-4021/PED

Start Date*: 2021-10-26

Sponsor Name:FAES FARMA S.A.

Full Title: A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria

Medical condition: Allergic rhinoconjunctivitis. Urticaria.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004853	10001728	Allergic rhinoconjunctivitis	LLT
	20.0	10040785 - Skin and subcutaneous tissue disorders	10046735	Urticaria	PT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: SK (Completed) LT (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2016-001505-17

Sponsor Protocol Number: BILA-3716/PRU

Start Date*: 2016-07-29

Sponsor Name:FAES FARMA, S.A.

Full Title: An exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases.

Medical condition: Chronic spontaneous urticaria and the following skin disorders: 1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermat...

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10040785 - Skin and subcutaneous tissue disorders	10012435	Dermatitis and eczema	HLT
	19.0	10040785 - Skin and subcutaneous tissue disorders	10037083	Prurigo	PT
	19.0	10040785 - Skin and subcutaneous tissue disorders	10052568	Urticaria chronic	PT

Population Age: Elderly

Gender: Male, Female

Trial protocol: ES (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2011-003248-36

Sponsor Protocol Number: 61383082

Start Date*: 2011-09-30

Sponsor Name:Central Military Hospital

Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.

Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.0	10018065 - General disorders and administration site conditions	10016335	Feeling hot and cold	LLT
	14.0	10040785 - Skin and subcutaneous tissue disorders	10037872	Rash NOS	LLT
	14.0	10037175 - Psychiatric disorders	10032168	Other insomnia	LLT
	14.0	10007541 - Cardiac disorders	10008481	Chest pain - cardiac	LLT
	14.0	10017947 - Gastrointestinal disorders	10064907	Functional abdominal pain	LLT
	14.0	10029205 - Nervous system disorders	10048324	Dizziness aggravated	LLT
	14.0	10029205 - Nervous system disorders	10033777	Paraesthesia distal	LLT
	14.0	10022891 - Investigations	10050786	Fasting blood glucose increased	LLT
	14.0	10018065 - General disorders and administration site conditions	10022096	Injection site reaction NOS	LLT
	14.0	10021881 - Infections and infestations	10034838	Pharyngitis NOS	LLT
	14.0	10018065 - General disorders and administration site conditions	10016259	Fatigueability	LLT
	14.0	10021428 - Immune system disorders	10020762	Hypersensitivity type I	LLT
	14.0	10028395 - Musculoskeletal and connective tissue disorders	10048412	Back pain aggravated	LLT
	14.0	10021428 - Immune system disorders	10020756	Hypersensitivity reaction	LLT
	14.0	10017947 - Gastrointestinal disorders	10028822	Nauseated	LLT
	14.0	10047065 - Vascular disorders	10048347	Flushing aggravated	LLT
	14.0	10029205 - Nervous system disorders	10024857	Loss of consiousness	LLT
	14.0	10029205 - Nervous system disorders	10019218	Headache NOS	LLT
	14.0	10040785 - Skin and subcutaneous tissue disorders	10037096	Pruritus NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed)

Trial results: (No results available)

EudraCT Number: 2006-004759-39

Sponsor Protocol Number: 06-02/Nyco-P

Start Date*: 2007-11-26

Sponsor Name:Dermapharm AG

Full Title: Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit einer Nystatin (100 000 I.E./g)/Hydrocortisonacetat (5 mg/g) -haltigen Paste vs. einer Nystatin (100 0...

Medical condition: Adult patients with moderate to severe inflamed candidiasis of the skin

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10040809	Skin candida NOS	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2012-002793-30

Sponsor Protocol Number: CLISO2

Start Date*: 2013-05-13

Sponsor Name:A.O. SAN GERARDO

Full Title: PHASE II RANDOMIZED STUDY FOR THE PREVENTION OF CUTANEOUS RASH INDUCED BY ERLOTINIB

Medical condition: metastatic inoperable tumour for NSCLC

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2012-002998-62

Sponsor Protocol Number: ROF-PSOR_104

Start Date*: 2012-12-13

Sponsor Name:Takeda Pharma A/S

Full Title: A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphod...

Medical condition: Mild to moderate, chronical, stable Psoriasis vulgaris

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2013-000300-42	Sponsor Protocol Number: 03AR0298	Start Date*: 2013-01-18
Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
Disease:
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2020-004047-86

Sponsor Protocol Number: AIS-A03

Start Date*: Information not available in EudraCT

Sponsor Name:Alpine Immune Sciences, Inc.

Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS

Medical condition: Systemic lupus erythematosus (SLE)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10040785 - Skin and subcutaneous tissue disorders	10042946	Systemic lupus erythematosus rash	PT
	21.1	10028395 - Musculoskeletal and connective tissue disorders	10042945	Systemic lupus erythematosus	PT
	21.1	10028395 - Musculoskeletal and connective tissue disorders	10042948	Systemic lupus erythematosus syndrome aggravated	LLT
	21.1	10028395 - Musculoskeletal and connective tissue disorders	10042947	Systemic lupus erythematosus synd	LLT
	20.0	100000004857	10029142	Nephritis systemic lupus erythematosus	LLT
	20.1	10022891 - Investigations	10067657	Systemic lupus erythematosus disease activity index increased	PT
	20.0	10022891 - Investigations	10067658	Systemic lupus erythematosus disease activity index decreased	PT
	20.1	10022891 - Investigations	10067659	Systemic lupus erythematosus disease activity index abnormal	PT
	21.0	10028395 - Musculoskeletal and connective tissue disorders	10080670	Systemic lupus erythematosus reactivation	LLT
	20.0	10038738 - Respiratory, thoracic and mediastinal disorders	10073694	Lupus pleurisy	PT
	21.1	10028395 - Musculoskeletal and connective tissue disorders	10040968	SLE arthritis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: FR (Completed) PL (Completed) ES (Prematurely Ended) HU (Completed)

Trial results: (No results available)

EudraCT Number: 2009-014582-51

Sponsor Protocol Number: MO-90020714

Start Date*: 2010-03-26

Sponsor Name:Faculty of Medicine, Technische Universität München

Full Title: Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels

Medical condition: Patients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis)

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.0		10002198	Anaphylactic reaction	LLT
	12.0		10040400	Serum sickness	LLT
	12.0		10043554	Thrombocytopenia	LLT
	12.0		10019211	Headache	LLT
	12.0		10028810	Nasopharyngitis	LLT
	12.0		10040753	Sinusitis	LLT
	12.0		10022000	Influenza	LLT
	12.0		10006451	Bronchitis	LLT
	12.0		10017888	Gastroenteritis	LLT
	12.0		10034835	Pharyngitis	LLT
	12.0		10047461	Viral infection	LLT
	12.0		10034844	Pharyngolaryngeal pain	LLT
	12.0		10011224	Cough	LLT
	12.0		10039083	Rhinitis	LLT
	12.0		10028735	Nasal congestion	LLT
	12.0		10039085	Rhinitis allergic	LLT
	12.0		10012727	Diarrhea	LLT
	12.0		10028813	Nausea	LLT
	12.0		10013946	Dyspepsia	LLT
	12.0		10003988	Back pain	LLT
	12.0		10003239	Arthralgia	LLT
	12.0		10028411	Myalgia	LLT
	12.0		10033425	Pain in extremity	LLT
	12.0		10041014	Sleepiness	LLT
	12.0		10046735	Urticaria	LLT
	12.0		10015587	Exanthema	LLT
	12.0		10037087	Pruritus	LLT
	12.0		10012485	Dermatitis photosensitive	LLT
	12.0		10000357	Accelerated hair loss	LLT
	12.0		10033775	Paraesthesia	LLT
	12.0		10042772	Syncope	LLT
	12.0		10064973	Allergic bronchospasm	LLT
	12.0		10001736	Allergic vasculitis	LLT
	12.0		10053354	Blood pressure orthostatic abnormal	LLT
	12.0		10063927	Orthostatic intolerance	LLT
	12.0		10000188	Abnormal weight gain	LLT
	12.0		10030095	Oedema	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2011-005471-17

Sponsor Protocol Number: RASH

Start Date*: 2012-05-08

Sponsor Name:Klinikum der Universität München-Großhadern

Full Title: Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors

Medical condition: metastatic pancreatic carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	100000004864	10033576	Pancreas carcinoma	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2017-000610-26

Sponsor Protocol Number: MK-4117-202

Start Date*: 2017-02-09

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.

Medical condition: Eczema/dermatitis and the dermal pruritus (itchy skin disease)

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.1	10040785 - Skin and subcutaneous tissue disorders	10012431	Dermatitis	PT
	19.1	10040785 - Skin and subcutaneous tissue disorders	10014184	Eczema	PT
	19.1	10040785 - Skin and subcutaneous tissue disorders	10037090	Pruritus cutaneous	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: Outside EU/EEA

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Skin rash